Aging, experts argue, is being misframed as a cosmetic problem when the real threat is chronic disease that compresses quality of life. Longevity startups chase senolytics and cellular reprogramming, yet most added years today are lived with diabetes, cardiovascular disease or neurodegeneration. Healthspan, not lifespan, is the missing metric in many glossy pitch decks and consumer products.
The sharper claim from clinicians is blunt: the biggest longevity win for most people is still controlling blood pressure, glucose and inflammation. That is where technology already bites. Continuous glucose monitors, home blood‑pressure cuffs linked to machine‑learning triage, and algorithms that detect atrial fibrillation from wearables all attack specific pathophysiology rather than some vague notion of “aging itself”.
What looks like modest risk reduction is, in aggregate, a radical longevity intervention. Cardiometabolic disease and cancer share upstream drivers such as chronic low‑grade inflammation and oxidative stress; targeting those early with precision diagnostics, polygenic risk scores and digital coaching platforms can delay multiple conditions at once. Anti‑aging compounds may yet reshape biology, but tools that cut hospitalizations and disability days already extend the only years that matter: the functional ones.
